QualityStocks would like to highlight Simulations Plus, Inc. (NASDAQ: SLP). The company designs and develops pharmaceutical simulation software for use in the pharmaceutical research and in the education of pharmacy and medical students. In addition, it offers contract research and consulting services to the pharmaceutical companies, plus designs and develops computer software, and manufactures augmentative communication devices and computer access products that provide a voice for those who cannot speak and allow physically disabled persons to operate a computer.
In the company’s news,
Simulations Plus announced it has accepted an invitation and signed a formal agreement to take part in the European Union Oral Bioavailability Tools (OrBiTo) project. Simulations Plus, a leader in providing simulation and modeling software for pharmaceutical discovery and development, has the honor of being the only non-European company that was invited to participate.
The OrBiTo project was created as part of the Innovative Medicines Initiative Joint Undertaking (IMI-JU). This new collaboration is intended to advance various tools – including computer software – that are used for predicting oral absorption of drugs. This will be accomplished by sharing data and technologies across the OrBiTo member companies.
A multiyear collaboration, the OrBiTo project will involve a total of 27 companies – from the largest pharmaceutical companies in the world to small companies, including some software companies. Simulations Plus will be the only company to participate that does not have an operational office in a European country. This distinction is a tribute to the company’s reputation for superior science and software on a global scale. Simulations Plus intends to leverage this invitation in its own marketing efforts, as well as with other OrBiTo member organizations. As a non-European member, Simulations Plus will receive funding for its efforts and also be granted access to important data to be shared equally among members. The company will thereby be in a better position to serve its European customers.
Simulations Plus is a leading developer of pioneering drug discovery and development simulation and modeling software – licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies throughout the world. Simulations Plus also provides a productivity tool called Abbreviate! for PCs. The company is headquartered in Southern California.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
